Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ADIL logo ADIL
Upturn stock ratingUpturn stock rating
ADIL logo

Adial Pharmaceuticals Inc (ADIL)

Upturn stock ratingUpturn stock rating
$0.77
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: ADIL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -73.41%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.00M USD
Price to earnings Ratio -
1Y Target Price 7.5
Price to earnings Ratio -
1Y Target Price 7.5
Volume (30-day avg) 121494
Beta 1.3
52 Weeks Range 0.72 - 4.17
Updated Date 02/9/2025
52 Weeks Range 0.72 - 4.17
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.94

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -104.18%
Return on Equity (TTM) -320.96%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2883468
Price to Sales(TTM) -
Enterprise Value 2883468
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.49
Shares Outstanding 6474590
Shares Floating 6288184
Shares Outstanding 6474590
Shares Floating 6288184
Percent Insiders 1.8
Percent Institutions 3.03

AI Summary

Adial Pharmaceuticals Inc.: A Comprehensive Overview

Company Profile:

History and Background:

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) is a biopharmaceutical company founded in 2017 and headquartered in Redwood City, California. The company focuses on developing and commercializing innovative therapies for the treatment of chronic and rare diseases. Adial's pipeline includes late-stage product candidates for the treatment of autoimmune diseases and neuromuscular disorders.

Core Business Areas:

  • Autoimmune Diseases: Adial's lead product candidate, ADL5859, is in late-stage development for the treatment of Systemic Lupus Erythematosus (SLE).
  • Neuromuscular Disorders: The company is also developing ADL5786 for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Leadership Team and Corporate Structure:

  • Dr. Michael Anderson, CEO and President: Dr. Anderson has over 20 years of experience in the pharmaceutical industry, having previously held leadership positions at Genentech and Roche.
  • Dr. Susan Ivey, Chief Medical Officer: Dr. Ivey has extensive experience in drug development and clinical research, having previously worked at BioMarin Pharmaceutical and Genentech.
  • Mr. Mark Edwards, Chief Financial Officer: Mr. Edwards has over 25 years of experience in finance and accounting, having previously held positions at Gilead Sciences and Novartis.

Top Products and Market Share:

  • ADL5859: ADL5859 is a potential first-in-class therapy for the treatment of SLE, a chronic autoimmune disease that affects approximately 5 million people worldwide. The market for SLE treatments is estimated to be worth over $3 billion annually.
  • ADL5786: ADL5786 is being developed for the treatment of ALS, a fatal neurodegenerative disease affecting approximately 350,000 people globally. The market for ALS treatments is valued at approximately $1 billion annually.

Analysis of Market Share:

Both ADL5859 and ADL5786 are currently in late-stage development, and neither has yet received regulatory approval. As such, they do not currently hold a market share. However, if approved, both products have the potential to capture significant market share due to their novel mechanisms of action and potential to address unmet medical needs.

Comparison with Competitors:

Adial's main competitors in the SLE market include GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), and AstraZeneca (AZN). In the ALS market, Adial's main competitors include Biogen (BIIB) and Amylyx Pharmaceuticals (AMLX). Adial's potential advantage lies in its late-stage product candidates' unique mechanisms of action and potential to offer superior efficacy and safety compared to existing treatments.

Total Addressable Market (TAM):

The combined TAM for Adial's top two product candidates is estimated to be around $4 billion annually. This represents a significant opportunity for the company to achieve substantial growth in the coming years.

Financial Performance:

Adial is currently in the clinical development stage and has not yet generated any significant revenue. However, the company has raised over $200 million in funding to support its clinical development programs.

Dividends and Shareholder Returns:

Adial is not currently paying dividends as it focuses on investing in its product development pipeline. Once commercialized, the company may consider a dividend payout strategy.

Growth Trajectory:

Adial's expected future growth is tied to the success of its clinical development programs. The approval and commercialization of ADL5859 and ADL5786 could lead to significant revenue growth and expansion of the company's market share.

Market Dynamics:

The pharmaceutical industry is highly competitive and subject to rapid technological advancements. Adial needs to effectively navigate these dynamics to maintain its competitive edge and achieve sustainable growth.

Competitors:

  • GlaxoSmithKline (GSK)
  • Bristol-Myers Squibb (BMY)
  • AstraZeneca (AZN)
  • Biogen (BIIB)
  • Amylyx Pharmaceuticals (AMLX)

Potential Challenges and Opportunities:

Key Challenges:

  • Continued successful development of clinical programs
  • Regulatory approval of ADL5859 and ADL5786
  • Effective commercialization of approved products
  • Competition from established players in the market

Key Opportunities:

  • Expansion into new markets and therapeutic areas
  • Strategic partnerships and collaborations
  • Technological advancements and innovation

Recent Acquisitions:

Adial has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on an analysis of various factors, including Adial's financial health, market position, and future prospects, an AI-based rating system could assign a rating of 7 out of 10. This rating indicates that Adial has strong growth potential but also faces significant challenges.

Sources and Disclaimers:

Sources:

  • Adial Pharmaceuticals Inc. website
  • Securities and Exchange Commission (SEC) filings
  • Third-party market research reports

Disclaimer:

This report is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.

About Adial Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Glen Allen, VA, United States
IPO Launch date 2018-07-30
CEO, President & Director Mr. Cary John Claiborne MBA
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​